We are excited to share with you that WuXi NextCODE has been selected by Genomics England (GeL) to provide clinical interpretation of the whole genome sequences of both rare disease and cancer patients as part of the first phase of the 100,000 Genomes Project (UK100K) of the UK National Health Service (NHS). After two rounds of head-to-head evaluation against leading sequence analysis providers from around the world, WuXi NextCODE is the only system selected by GeL in all categories.
WuXi NextCODE will deploy its unique database model and clinical and tumor-normal analysis and reporting systems at GeL, enabling NHS clinicans to begin to efficiently analyze patient sequence data and to identify causative variants in rare diseases and driver mutations in tumors. GeL plans to sequence and interpret the genome of 8,000 patients in this initial phase of the UK100K project and to test the systems prior to contracting with the four winning companies.
GeL is a pioneer in the global movement to realize precision medicine at scale, and we are honored to play a part in delivering on this vision in the UK and around the world.